Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

PURPOSE: Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. METHODS: Patients who received anti–PD-1/PD-L1 monotherapy or in co...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Naidoo, Jarushka, Wang, Xuan, Woo, Kaitlin M., Iyriboz, Tunc, Halpenny, Darragh, Cunningham, Jane, Chaft, Jamie E., Segal, Neil H., Callahan, Margaret K., Lesokhin, Alexander M., Rosenberg, Jonathan, Voss, Martin H., Rudin, Charles M., Rizvi, Hira, Hou, Xue, Rodriguez, Katherine, Albano, Melanie, Gordon, Ruth-Ann, Leduc, Charles, Rekhtman, Natasha, Harris, Bianca, Menzies, Alexander M., Guminski, Alexander D., Carlino, Matteo S., Kong, Benjamin Y., Wolchok, Jedd D., Postow, Michael A., Long, Georgina V., Hellmann, Matthew D.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2017
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559901/
https://ncbi.nlm.nih.gov/pubmed/27646942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.68.2005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars